Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Cash & Current Investments (2016 - 2025)

Capricor Therapeutics has reported Cash & Current Investments over the past 15 years, most recently at $318.1 million for Q4 2025.

  • Quarterly results put Cash & Current Investments at $318.1 million for Q4 2025, up 109.96% from a year ago — trailing twelve months through Dec 2025 was $318.1 million (up 109.96% YoY), and the annual figure for FY2025 was $318.1 million, up 109.96%.
  • Cash & Current Investments for Q4 2025 was $318.1 million at Capricor Therapeutics, up from $98.6 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for CAPR hit a ceiling of $318.1 million in Q4 2025 and a floor of $28.5 million in Q3 2023.
  • Median Cash & Current Investments over the past 5 years was $43.5 million (2021), compared with a mean of $74.7 million.
  • Biggest five-year swings in Cash & Current Investments: crashed 38.81% in 2023 and later skyrocketed 316.81% in 2025.
  • Capricor Therapeutics' Cash & Current Investments stood at $34.9 million in 2021, then rose by 18.74% to $41.4 million in 2022, then dropped by 4.67% to $39.5 million in 2023, then skyrocketed by 283.7% to $151.5 million in 2024, then surged by 109.96% to $318.1 million in 2025.
  • The last three reported values for Cash & Current Investments were $318.1 million (Q4 2025), $98.6 million (Q3 2025), and $122.8 million (Q2 2025) per Business Quant data.